Chinese Team Develops "Smart Targeted Nanomedicine" Inspired by Viruses, Enabling Precise Targeting of Osteoarthritic Cells and Achieving Long-Term Intra-Articular Retention
Today, we share a significant study published in Nature Nanotechnologyby a collaborative team led by Jiacan Su from Shanghai Jiao Tong University and Xiaoyuan Chen from the National University of Singapore, among others. This research tackles the major challenge of inefficient drug delivery to diseased chondrocytes in osteoarthritis (OA) therapy. Inspired by viral infection mechanisms, the team designed a nanomicelle functionalized with a virus glycoprotein-mimetic peptide. This intelligent delivery system achieves simultaneous cartilage tissue retention and specific uptake by diseased cells, demonstrating remarkable cartilage protection in both small and large animal models. It offers an efficient nanodelivery platform for developing disease-modifying osteoarthritis drugs (DMOADs).
01 Research Background
Osteoarthritis (OA) is a major global health concern, affecting approximately 500 million people and leading to chronic pain, functional decline, and a substantial socioeconomic burden. A key bottleneck hindering the development of approved DMOADs that can reverse the disease process is the inability to efficiently deliver drugs to diseased chondrocytes. While intra-articular injection increases local drug concentration, free drugs are rapidly cleared (within hours) by synovial fluid. Nanoparticles can extend retention but face dual barriers: 1) penetration blockage by the dense type II collagen network (pore size ~60 nm), and 2) the lack of ligands that specifically recognize and internalize into diseased chondrocytes, as existing ligands (e.g., cRGD peptide) cannot distinguish healthy from diseased cells. Viruses have evolved efficient mechanisms for delivering genetic material into host cells; their surface glycoproteins mediate tissue retention and, upon activation by specific signals (e.g., proteases), facilitate cellular internalization. Inspired by this, the study aimed to develop a novel nanomedicine mimicking this intelligent viral delivery behavior.
02 Innovative Highlights
- Biomimetic Design Innovation: A Multifunctional Virus Glycoprotein-Mimetic Peptide (CMP)
The team designed a novel peptide, CMP (sequence: WYRGRL-PEG3-e9-C6-(GPLGVRG)-r9-C6-Cys), featuring two key modules: "Capture-Retention" Module (WYRGRL): Mimics viral surface adhesion structures, specifically binding to type II collagen in the cartilage matrix and on cell surfaces to enable long-term nanoparticle retention within the joint.
"Protease-Activated Cell-Penetrating" Module (e9-(GPLGVRG)-r9): Mimics viral protease-activated internalization. This sequence is cleaved by matrix metalloproteinase 13 (MMP13), overexpressed in diseased chondrocytes, exposing the positively charged cell-penetrating peptide (r9) to drive specific nanoparticle entry into target cells.
- Delivery Strategy Innovation: Synergistic Achievement of "Tissue Retention" and "Cell-Specific Uptake"
Conjugating the CMP peptide onto small-sized (~16 nm) micelles (CM-Ms) allows penetration of the intact cartilage matrix. This dual-mechanism strategy simultaneously addresses the core challenges of drugs both "staying" at the lesion site and "entering" the target cells.
- Therapeutic Strategy Innovation: Precise Delivery of an HIF-1α Stabilizer to Restore Cartilage Metabolic Homeostasis
The team selected IOX4, a prolyl hydroxylase 2 (PHD2) inhibitor that stabilizes hypoxia-inducible factor-1α (HIF-1α), as the model drug. The study confirmed that HIF-1α downregulation is a key factor in cartilage metabolic imbalance during OA progression. CM-Ms@IOX4 efficiently delivers IOX4 to diseased chondrocytes, persistently stabilizing HIF-1α levels to promote matrix synthesis and inhibit degradation, fundamentally slowing OA progression.
03 Results and Discussion
3.1 Successful Preparation and Characterization of CMP Micelles
CMP-functionalized, IOX4-loaded micelles (CM-Ms@IOX4) were successfully prepared via thin-film hydration. Dynamic light scattering and TEM confirmed uniform spherical particles (~16 nm) capable of penetrating cartilage. Zeta potential analysis showed CMP modification yielded a near-neutral surface. After MMP13 treatment, cleavage of the polyglutamate sequence shifted the potential significantly positive (+7.43 mV), confirming enzyme-responsive activation. The micelles exhibited high drug loading (5.86%), sustained release, and good stability.
3.2 In Vitro Validation of Specific Uptake and Cartilage Penetration
In an IL-1β-induced diseased chondrocyte model, flow cytometry and confocal microscopy showed CM-Ms had the highest cellular uptake, significantly exceeding unmodified micelles (Ms), collagen-binding peptide-only micelles (C-Ms), or MMP13-responsive peptide-only micelles (M-Ms). Uptake was inhibited by an MMP13-specific inhibitor, confirming MMP13-dependence. In a microfluidic model simulating synovial flushing, CM-Ms demonstrated superior retention and specific targeting to MMP13-positive diseased chondrocytes in human cartilage explants.
3.3 In Vivo Joint Retention and Targeted Delivery Efficacy
In a mouse OA model, in vivoimaging showed a single intra-articular injection of CM-Ms resulted in joint retention for over 38 days, with an AUC 2.45 times that of unmodified Ms. Critically, tissue section analysis confirmed CM-Ms@C6 (fluorescent marker) fluorescence intensity in diseased cartilage was far higher than in normal areas (diseased/normal ratio up to 9.26), demonstrating excellent targeting specificity absent in control groups.
3.4 Outstanding Therapeutic Efficacy and Mechanistic Insights
In the mouse OA model, CM-Ms@IOX4 treatment significantly alleviated pain and improved joint function. Histology (H&E, Safranin O) showed it most effectively maintained cartilage thickness, reduced OARSI scores, and inhibited osteophyte formation. Mechanistically, CM-Ms@IOX4 significantly increased HIF-1α protein levels in diseased chondrocytes, upregulating matrix components (COL2, ACAN) and downregulating catabolic enzymes (MMP13, ADAMTS-5), successfully reversing metabolic imbalance.
3.5 Preclinical Validation in a Large Animal Model
In a clinically relevant sheep OA model, CM-Ms@IOX4 treatment significantly improved standing and walking gait. MRI and histology consistently showed effective protection of cartilage and subchondral bone structure, with effects surpassing clinically used hyaluronic acid and free IOX4, meeting DMOAD criteria.
04 Conclusion and Future Perspectives
This study successfully developed a virus glycoprotein-mimetic smart peptide and its nanodelivery system, effectively addressing the core bottleneck of targeted drug delivery in OA. This platform not only provides an efficient delivery solution for DMOADs like IOX4 requiring sustained intracellular action but also offers a modular design with broad applicability. Its significance lies in the seamless integration of biomimetic principles and nanomedicine, establishing a new paradigm for precise drug delivery to deep tissue and specific cells. Future applications of the CMP platform could include delivering other therapies hindered by poor intracellular delivery in clinical trials, such as genetic drugs (siRNA, mRNA) or metabolic modulators. With its components (DSPE-PEG) already FDA-approved for other drugs and a scalable preparation process, this nanoplatform holds strong potential for rapid clinical translation. In summary, this research offers new hope for tackling OA and advances the development of intelligent nanomedicines in regenerative medicine.
Orginal Article：
Chen X, Zhou D, Wang J, Liu H, Zhang H, Geng Z, Wang G, Shen H, Zhang Y, Li Z, Wang D, Ren X, Wang X, Xu K, He C, Bai L, Wei Y, Chen X, Su J. Viral glycoprotein-mimicking peptide-functionalized micelles promote drug delivery to diseased chondrocytes for osteoarthritis alleviation. Nat Nanotechnol. 2025 Dec 29.